The European Heart Rhythm Association (EHRA) updated its practical guide on use of non-vitamin K antagonist oral anticoagulants in specific clinical situations and particular patient groups.
Defining statin eligibility based on the predicted CV benefit, rather than the absolute CV risk, shifts statin eligibility to more intermediate CV risk subjects.
In a large, prospective, population-based cohort, waist-to-hip ratio was more strongly associated with the risk of MI compared with BMI, especially in women.
During the CV summit of the European Primary Care Cardiovascular Society in Barcelona, GPs from 19 different European countries were informed about the latest treatment and management options and it was discussed how the Society could support European primary cardiovascular care in a better way.
New data of the ongoing GLORIA-AF registry on use of dabigatran in AF show low rates of major bleeding and stroke, and long-term safety data are consistent with other real-world and RCT evidence.
A meta-analysis of available CV outcome trials with GLP-1 receptor agonists shows that they reduce major adverse cardiovascular events in type 2 diabetes patients without significant safety concerns.
Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.
Latest frontiers in anticoagulation therapy Prof. John Eikelboom discusses the indications for reversal of anticoagulation and results of trials with the available reversal agents.
ACC 2018 Steven Nissen compares ODYSSEY OUTCOMES with FOURIER and concludes that the results of these 2 studies in 2 different patient populations reinforce our understanding of the benefit of reducing LDL-c levels in patients with moderate LDL-c levels.
ACC 2018 Prof. Ray considers current insights on the class of PCSK9 inhibiting monoclonal antibodies, and he looks ahead at another PCSK9 inhibiting agent.
Maintaining or increasing physical activity was associated with substantial reductions in CVD mortality risk, in a large cohort of patients with angina pectoris or myocardial infarction.
ACC 2018 A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.